- Home
- SD vs NMRA Comparison
SD vs NMRA Comparison
Compare SD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- NMRA
- Stock Information
- Founded
- SD 2006
- NMRA 2019
- Country
- SD United States
- NMRA United States
- Employees
- SD 104
- NMRA N/A
- Industry
- SD Oil & Gas Production
- NMRA
- Sector
- SD Energy
- NMRA
- Exchange
- SD Nasdaq
- NMRA Nasdaq
- Market Cap
- SD 351.0M
- NMRA 287.6M
- IPO Year
- SD 2007
- NMRA 2023
- Fundamental
- Price
- SD $9.62
- NMRA $0.65
- Analyst Decision
- SD
- NMRA Buy
- Analyst Count
- SD 0
- NMRA 8
- Target Price
- SD N/A
- NMRA $9.29
- AVG Volume (30 Days)
- SD 395.1K
- NMRA 1.2M
- Earning Date
- SD 05-06-2025
- NMRA 05-06-2025
- Dividend Yield
- SD 4.62%
- NMRA N/A
- EPS Growth
- SD 3.05
- NMRA N/A
- EPS
- SD 1.69
- NMRA N/A
- Revenue
- SD $125,290,000.00
- NMRA N/A
- Revenue This Year
- SD $37.50
- NMRA N/A
- Revenue Next Year
- SD $5.17
- NMRA N/A
- P/E Ratio
- SD $5.69
- NMRA N/A
- Revenue Growth
- SD N/A
- NMRA N/A
- 52 Week Low
- SD $8.81
- NMRA $0.62
- 52 Week High
- SD $14.85
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- SD 40.02
- NMRA 22.34
- Support Level
- SD $9.14
- NMRA $0.64
- Resistance Level
- SD $9.77
- NMRA $0.83
- Average True Range (ATR)
- SD 0.51
- NMRA 0.09
- MACD
- SD -0.07
- NMRA 0.02
- Stochastic Oscillator
- SD 29.24
- NMRA 6.68
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.